Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

5-Amino-1MQ (NNMT inhibitor): does it work, is it legal, and what does it cost?

Not a peptide: an oral blocker of NNMT, an enzyme overactive in fat tissue, that cut fat in obese mice; no human trial published; not approved or compoundable.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about 5-Amino-1MQ
Does it work in people?Evidence: Animal-only evidence

No randomized human trial of this peptide; the grade rests on animal and lab studies. See the evidence

Is it legal?Regulatory: Unscheduled

Not FDA approved and not on FDA's list of substances pharmacies may compound (the 503A bulks list), so a pharmacy has no federal basis to compound it. [3] [4] See legal status

What does it cost?Not available through licensed channels. Insurance does not cover it. See cost by channel
Side effects?No human safety data of any kind published. Mild nausea, headache, and appetite changes reported anecdotally. Long term effects of NNMT inhibition (which alters NAD+ and methylation balance) in humans are unknown. See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is 5-Amino-1MQ?

5-Amino-1MQ is a small molecule (a simple chemical drug, not a peptide) that blocks nicotinamide N-methyltransferase (NNMT), an enzyme that is overactive in fat tissue in obesity. In mice made obese by a high fat diet it reduced body weight and white fat mass (the body's main fat stores) over 11 days, and in aged mice it improved the function of muscle stem cells, the cells that repair muscle. No human trial of any kind has been published, it has no FDA approval or legal route to be compounded (custom-made by a pharmacy), and because it is unapproved everywhere it falls under WADA's S0 ban on unapproved substances.

5-Amino-1MQ is an oral small molecule nicotinamide N-methyltransferase (NNMT) inhibitor; not a peptide. It is also known as 5-amino-1-methylquinolinium, 5-amino-1-methylquinolin-1-ium, 5A1MQ, NNMT inhibitor 5-amino-1MQ, 5 amino 1mq, 5-amino-1MQ, 5-amino 1MQ.

How does it work?

NNMT consumes nicotinamide and S-adenosylmethionine, lowering NAD+ precursors and the cell's methylation capacity; its expression rises in adipose tissue in obesity. 5-Amino-1MQ is a membrane permeable quinolinium compound that selectively inhibits NNMT, which in mouse adipocytes increases NAD+ and SAM, reduces lipogenesis, and increases energy expenditure. The compound also activated senescent muscle stem cells in aged mice. None of this has been demonstrated in humans.

Key facts
ClusterMetabolic and growth hormone axis
RoutesOral capsule (as sold); Subcutaneous or intraperitoneal injection and oral gavage (mouse studies)
Conditions studiedObesity and chronic weight management; Fat loss and body composition
Recordv3, reviewed, verified Sep 22, 2026

5-amino-1MQ benefits: what the evidence shows

Evidence: Animal-only evidenceGrade assigned per the methodology.

Two mouse studies from one University of Texas group. Neelakantan 2018: in diet induced obese mice, 11 days of 5-amino-1MQ reduced body weight, white adipose mass, and adipocyte size and lowered plasma cholesterol, without reducing food intake proportionally. Neelakantan 2019: in aged mice the compound activated senescent muscle stem cells and improved regeneration after injury. No human pharmacokinetic, safety, or efficacy study has been published as of the last verification date.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials0n/a
Human observational studies0n/a
Animal studies2n/a
All indexed studies2n/a

Human evidence

No indexed human study identified. Claims of fat loss, muscle gain, or metabolic benefit in people are extrapolated from mouse data and from vendor testimonials.

Animal evidence

Neelakantan 2018 (Biochem Pharmacol): diet induced obese mice given 5-amino-1MQ for 11 days lost body weight and white fat mass relative to vehicle, with smaller adipocytes and lower cholesterol; the compound was selective for NNMT and orally available. Neelakantan 2019 (Biochem Pharmacol): in 24 month old mice the inhibitor activated muscle stem cells and improved muscle regeneration and contractile function after injury. No long term toxicology has been published.

Key studies

Indexed studies of 5-Amino-1MQ
StudyDesign and populationOutcomeGrade
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice2018 PMID 29155147Mouse diet induced obesity model, 11 day treatmentDiet induced obese miceReduced body weight, white adipose mass, adipocyte size, and plasma cholesterol versus vehicleEvidence: Animal-only evidence
Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle2019 PMID 30753815Aged mouse muscle injury model24 month old miceActivated muscle stem cells and improved regeneration and contractile recovery after injuryEvidence: Animal-only evidence

Conditions studied

Conditions with evidence for 5-Amino-1MQ
ConditionGradeNote
Obesity and chronic weight managementNot gradedGLP-1 based peptides are the only peptides with large randomized trials for weight loss. Semaglutide 2.4 mg produced 14.9% mean weight loss over 68 weeks and tirzepatide 15 mg produced 20.9% over 72 weeks. Retatrutide, cagrilintide, and survodutide are in late stage trials.
Fat loss and body compositionEvidence: Animal-only evidenceSmall molecule NNMT inhibitor that reduced fat mass in diet induced obese mice; no human studies.

Is 5-Amino-1MQ legal in the United States?

Regulatory: UnscheduledWADA: WADA prohibited

FDA and compounding status

Not FDA approved and not an active ingredient in any approved drug. It does not appear in FDA's Category 2 list or on the 503A bulks list as of the pages current to April 2026, and it has no USP monograph, so it does not meet any of the three bulk substance criteria in section 503A. That leaves no federal basis for a compounding pharmacy to compound it despite its widespread marketing as a compounded capsule. It was not part of the July 2026 advisory committee review.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

No regulatory events recorded.

Full tracker for 5-Amino-1MQ or the category-wide tracker.

Email me when 5-Amino-1MQ's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of 5-Amino-1MQ used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Not established in human literature. Mouse studies used low milligram per kilogram daily doses (5 and 10 mg/kg in the aged muscle study); these rodent doses do not translate to a human regimen and no human dose finding study exists.

Routes reported

Routes of administration reported for 5-Amino-1MQ
#Route
1Oral capsule (as sold)
2Subcutaneous or intraperitoneal injection and oral gavage (mouse studies)

5-amino-1MQ side effects

Side effects

Side effects reported for 5-Amino-1MQ
#Reported side effect
1No human safety data of any kind published
2Mild nausea, headache, and appetite changes reported anecdotally
3Long term effects of NNMT inhibition (which alters NAD+ and methylation balance) in humans are unknown

Interactions

Interactions reported for 5-Amino-1MQ
#Interaction
1No human interaction data exist
2Theoretical interaction with NAD+ precursors (nicotinamide, NMN, NR) because NNMT metabolizes nicotinamide

Contraindications

Contraindications for 5-Amino-1MQ
#Contraindication
1Pregnancy and breastfeeding (no data)
2Athletes subject to WADA testing (prohibited at all times under S0 as a non-approved substance)
3Any use requiring an approved product: none exists

How do people access 5-Amino-1MQ legally?

Typical cost: Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Access options

  • Not available

    No lawful United States access path identified on the last verified date: it is not FDA approved and is not on the 503A bulks list.

  • Not available

    Not available as an FDA approved product, not nominated for the 503A bulks list, and not eligible for compounding under section 503A or 503B.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare 5-Amino-1MQ

What's actually offered, and what that means for you

FDA has found an outsourcing facility offering 5-Amino-1MQ anyway. [7]

Being offered does not change the legal status of 5-Amino-1MQ. 5-Amino-1MQ is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [3] [4]

What FDA found

  • January 2026: FDA told a 503B outsourcing facility that drugs it made from 5-amino-1MQ were not eligible under section 503B, and cited insanitary sterile conditions. [7]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [4] [8] [9] [10] [11] [12]

What that means for you

  • A pharmacy that compounds 5-Amino-1MQ is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [8] [9]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [12]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [13]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [14] [15]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [4]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, 5-Amino-1MQ is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [5]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound 5-Amino-1MQ, with or without a prescription. [3]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [16] [17] [18]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [18] [19] [20]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [12] [21] [22] [23] [24] [25]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [12]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [16]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [20]
  • Pharmacy: Is this made for me on a prescription written in my name? [19]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [18] [20]
  • Prescriber: What is the legal basis for a pharmacy to compound 5-Amino-1MQ? Is it FDA approved or on the 503A bulks list? [3] [12]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [20]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [13]

Frequently asked questions

What is 5-Amino-1MQ?

5-Amino-1MQ is a small molecule, not a peptide, that blocks nicotinamide N-methyltransferase (NNMT), an enzyme that is overactive in fat tissue in obesity. It is sold as capsules for fat loss and muscle, but its only published evidence is two short mouse studies. It is not FDA approved, is not on the 503A bulks list (FDA's list of raw ingredients pharmacies may use to compound drugs for individual patients), and has no lawful compounded source. [1] [2] [3]

Is 5-Amino-1MQ legal in the United States?

It is not FDA approved, is not on the 503A bulks list, and has no USP monograph, so a compounding pharmacy has no federal basis to compound it even though it is widely marketed as a compounded capsule. It is also absent from FDA's Category 2 list, which means FDA has not formally reviewed it, not that it has been cleared. Possession is not a crime. [3] [4]

5-Amino-1MQ benefits: does it work for fat loss?

In diet induced obese mice, an 11 day course reduced body weight and white fat mass and shrank fat cells. In humans there is no evidence either way, because no clinical trial has been published. PeptideAgent grades it animal-only. [1]

What are the side effects of 5-Amino-1MQ?

Unknown. No human safety, pharmacokinetic, or toxicology study has been published. Anecdotal reports mention nausea, headache, and appetite changes. Because NNMT inhibition changes NAD+ and methylation balance throughout the body, long term effects cannot be predicted from the two short mouse studies. [1] [2]

How is 5-Amino-1MQ taken?

Products sold online are oral capsules. The mouse studies gave it by injection or by mouth, and their doses do not translate to people. No human dose has been established. PeptideAgent does not give doses for unapproved peptides. [1]

How much does 5-Amino-1MQ cost?

There is no licensed price because no lawful product exists, and purity of these products is not verified. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [3] [6]

Is 5-Amino-1MQ banned by WADA?

It is not named on the list, but section S0 of the WADA Prohibited List prohibits at all times any pharmacological substance that has no current approval by a governmental health authority for human therapeutic use. 5-Amino-1MQ has no approval anywhere, so it falls under S0. [5]

Is 5-Amino-1MQ a peptide?

No. It is a small aromatic molecule (a methylquinolinium salt). It is sold by peptide vendors and clinics alongside injectable peptides, which is the only reason it appears in peptide directories. [1]

Does 5-Amino-1MQ build muscle?

In 24 month old mice, NNMT inhibition activated senescent muscle stem cells and improved regeneration after injury. That is a repair finding in old animals, not a muscle building finding, and it has not been tested in people. [2]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol 2018PubMed 29155147, 2018
  2. [2]Neelakantan H et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol 2019PubMed 30753815, 2019
  3. [3]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  4. [4]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  5. [5]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  6. [6]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  7. [7]FDA warning letter 718739, January 20, 2026, to a 503B outsourcing facility (FDA warning letters database)FDA, 2026
  8. [8]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
  9. [9]FDA warning letter 579286, July 30, 2019, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2019
  10. [10]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides (FDA warning letters database)FDA, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 22). 5-Amino-1MQ: evidence, legality, and access. https://peptideagent.ai/peptides/5-amino-1mq
HTML link
<a href="https://peptideagent.ai/peptides/5-amino-1mq">5-Amino-1MQ: evidence, legality, and access</a>, PeptideAgent, updated September 22, 2026.